|
1
|
Xie L, Dai H, Li M, Yang W, Yu G, Wang X,
Wang P, Liu W, Hu X and Zhao M: MARCH1 encourages tumour
progression of hepatocellular carcinoma via regulation of
PI3K-AKT-β-catenin pathways. J Cell Mol Med. 23:3386–3401.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Syed YY: Ramucirumab: A review in
hepatocellular carcinoma. Drugs. 80:315–322. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cui H, Dai G and Guan J: Programmed cell
death protein-1 (PD-1)-targeted immunotherapy for advanced
hepatocellular carcinoma in real world. Onco Targets Ther.
13:143–149. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kirstein MM and Wirth TC: Multimodal
treatment of hepatocellular carcinoma. Internist (Berl).
61:164–169. 2020.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
7
|
Metzger E, Yin N, Wissmann M, Kunowska N,
Fischer K, Friedrichs N, Patnaik D, Higgins JM, Potier N,
Scheidtmann KH, et al: Phosphorylation of histone H3 at threonine
11 establishes a novel chromatin mark for transcriptional
regulation. Nat Cell Biol. 10:53–60. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Jilg CA, Ketscher A, Metzger E, Hummel B,
Willmann D, Rüsseler V, Drendel V, Imhof A, Jung M, Franz H, et al:
PRK1/PKN1 controls migration and metastasis of androgen-independent
prostate cancer cells. Oncotarget. 5:12646–12664. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mukai H: The structure and function of
PKN, a protein kinase having a catalytic domain homologous to that
of PKC. J Biochem. 133:17–27. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dong LQ, Landa LR, Wick MJ, Zhu L, Mukai
H, Ono Y and Liu F: Phosphorylation of protein kinase N by
phosphoinositide-dependent protein kinase-1 mediates insulin
signals to the actin cytoskeleton. Proc Natl Acad Sci USA.
97:5089–5094. 2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yasui T, Sakakibara-Yada K, Nishimura T,
Morita K, Tada S, Mosialos G, Kieff E and Kikutani H: Protein
kinase N1, a cell inhibitor of Akt kinase, has a central role in
quality control of germinal center formation. Proc Natl Acad Sci
USA. 109:21022–21027. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lachmann S, Jevons A, De Rycker M,
Casamassima A, Radtke S, Collazos A and Parker PJ: Regulatory
domain selectivity in the cell-type specific PKN-dependence of cell
migration. PLoS One. 6(e21732)2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cuny GD: Kinase inhibitors as potential
therapeutics for acute and chronic neurodegenerative conditions.
Curr Pharm Des. 15:3919–3939. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Galgano MT, Conaway M, Spencer AM, Paschal
BM and Frierson HF Jr: PRK1 distribution in normal tissues and
carcinomas: Overexpression and activation in ovarian serous
carcinoma. Hum Pathol. 40:1434–1440. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Attarha S, Saini RK, Andersson S, Mints M
and Souchelnytskyi S: PKN1 modulates TGFβ and EGF signaling in
HEC-1-A endometrial cancer cell line. Onco Targets Ther.
7:1397–1408. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zeng R, Wang Z, Li X, Chen Y, Yang S and
Dong J: Cyclin-dependent kinase 1-mediated phosphorylation of
protein kinase N1 promotes anchorage-independent growth and
migration. Cell Signal. 69(109546)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Deaton RA, Su C, Valencia TG and Grant SR:
Transforming growth factor-beta1-induced expression of smooth
muscle marker genes involves activation of PKN and p38 MAPK. J Biol
Chem. 280:31172–31181. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang CS, Melhuish TA, Spencer A, Ni L, Hao
Y, Jividen K, Harris TE, Snow C, Frierson HF, Wotton D and Paschal
BM: The protein kinase C super-family member PKN is regulated by
mTOR and influences differentiation during prostate cancer
progression. Prostate. 77:1452–1467. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
James RG, Bosch KA, Kulikauskas RM, Yang
PT, Robin NC, Toroni RA, Biechele TL, Berndt JD, von Haller PD, Eng
JK, et al: Protein kinase PKN1 represses Wnt/β-catenin signaling in
human melanoma cells. J Biol Chem. 288:34658–34670. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Park BV, Gaba RC, Huang YH, Chen YF,
Guzman G and Lokken RP: Histology of hepatocellular carcinoma:
Association with clinical features, radiological findings, and
locoregional therapy outcomes. J Clin Imaging Sci.
9(52)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhou L, Rui JA, Zhou WX, Wang SB, Chen SG
and Qu Q: Edmondson-Steiner grade: A crucial predictor of
recurrence and survival in hepatocellular carcinoma without
microvascular invasion. Pathol Res Pract. 213:824–830.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Faivre S, Rimassa L and Finn RS: Molecular
therapies for HCC: Looking outside the box. J Hepatol. 72:342–352.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jonas S, Bechstein WO, Steinmüller T,
Herrmann M, Radke C, Berg T, Settmacher U and Neuhaus P: Vascular
invasion and histopathologic grading determine outcome after liver
transplantation for hepatocellular carcinoma in cirrhosis.
Hepatology. 33:1080–1086. 2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhou L, Rui JA, Wang SB, Chen SG and Qu Q:
Clinicopathological predictors of poor survival and recurrence
after curative resection in hepatocellular carcinoma without portal
vein tumor thrombosis. Pathol Oncol Res. 21:131–138.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang W, Kim R, Quintini C, Hashimoto K,
Fujiki M, Diago T, Eghtesad B, Miller C, Fung J, Tan A, et al:
Prognostic role of plasma vascular endothelial growth factor in
patients with hepatocellular carcinoma undergoing liver
transplantation. Liver Transpl. 21:101–111. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Raoul JL and Edeline J: Systemic treatment
of hepatocellular carcinoma: Standard of care in China and
elsewhere. Lancet Oncol. 21:479–481. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tong X, Wang Q, Wu D, Bao L, Yin T and
Chen H: MEK inhibition by cobimetinib suppresses hepatocellular
carcinoma and angiogenesis in vitro and in vivo. Biochem Biophys
Res Commun. 523:147–152. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Berretta M, Cobellis G, Franco R, Panarese
I, Rinaldi B, Nasti G, Di Francia R and Rinaldi L: Features of
microvessel density (MVD) and angiogenesis inhibitors in
therapeutic approach of hepatocellular carcinoma (HCC). Eur Rev Med
Pharmacol Sci. 23:10139–10150. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Mukai H, Muramatsu A, Mashud R, Kubouchi
K, Tsujimoto S, Hongu T, Kanaho Y, Tsubaki M, Nishida S, Shioi G,
et al: PKN3 is the major regulator of angiogenesis and tumor
metastasis in mice. Sci Rep. 6(18979)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Santel A, Aleku M, Röder N, Möpert K,
Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, et al:
Atu027 prevents pulmonary metastasis in experimental and
spontaneous mouse metastasis models. Clin Cancer Res. 16:5469–5480.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stroescu C, Dragnea A, Ivanov B, Pechianu
C, Herlea V, Sgarbura O, Popescu A and Popescu I: Expression of
p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in
hepatocellular carcinoma. J Gastrointestin Liver Dis. 17:411–417.
2008.PubMed/NCBI
|
|
33
|
Xie L, Li M, Liu D, Wang X, Wang P, Dai H,
Yang W, Liu W, Hu X and Zhao M: Secalonic Acid-F, a novel
mycotoxin, represses the progression of hepatocellular carcinoma
via MARCH1 regulation of the PI3K/AKT/β-catenin signaling pathway.
Molecules. 24(393)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Turner EC, Kavanagh DJ, Mulvaney EP,
McLean C, Wikström K, Reid HM and Kinsella BT: Identification of an
interaction between the TPand TP isoforms of the human thromboxane
A2 receptor with protein kinase C-related kinase (PRK) 1.
Implications for prostate cancer. J Biol Chem. 286:15440–15457.
2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Owen D, Lowe PN, Nietlispach D, Brosnan
CE, Chirgadze DY, Parker PJ, Blundell TL and Mott HR: Molecular
dissection of the interaction between the small G proteins Rac1 and
RhoA and protein kinase C-related kinase 1 (PRK1). J Biol Chem.
278:50578–50587. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Modha R, Campbell LJ, Nietlispach D,
Buhecha HR, Owen D and Mott HR: The Rac1 polybasic region is
required for interaction with its effector PRK1. J Biol Chem.
283:1492–1500. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Takahashi M, Mukai H, Toshimori M,
Miyamoto M and Ono Y: Proteolytic activation of PKN by caspase·3 or
related protease during apoptosis. Proc Natl Acad Sci USA.
95:11566–11571. 1998.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ueyama T, Ren Y, Sakai N, Takahashi M, Ono
Y, Kondoh T, Tamaki N and Saito N: Generation of a constitutively
active fragment of PKN in microglia/macrophages after middle
cerebral artery occlusion in rats. J Neurochem. 79:903–913.
2001.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cryns VL, Byun Y, Rana A, Mellor H, Lustig
KD, Ghanem L, Parker PJ, Kirschner MW and Yuan J: Specific
proteolysis of the kinase protein kinase C-related kinase 2 by
caspase·3 during apoptosis. Identification by a novel, small pool
expression cloning strategy. J Biol Chem. 272:29449–29453.
1997.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Koh H, Lee KH, Kim D, Kim S, Kim JW and
Chung J: Inhibition of Akt and its anti-apoptotic activities by
tumor necrosis factor-induced protein kinase C-related kinase 2
(PRK2) cleavage. J Biol Chem. 275:34451–34458. 2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Aittomäki S and Pesu M: Therapeutic
targeting of the Jak/STAT pathway. Basic Clin Pharmacol Toxicol.
114:18–23. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ostrovskyi D, Rumpf T, Eib J, Lumbroso A,
Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M,
Pfaffenrot E, et al: Tofacitinib and analogs as inhibitors of the
histone kinase PRK1 (PKN1). Future Med Chem. 8:1537–1551.
2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hosseini A, Gharibi T, Marofi F, Javadian
M, Babaloo Z and Baradaran B: Janus kinase inhibitors: A
therapeutic strategy for cancer and autoimmune diseases. J Cell
Physiol. 235:5903–5924. 2020.PubMed/NCBI View Article : Google Scholar
|
